Journal of Internal Medicine

Background and AimMASLD affects 30-38% of Indian adults, yet the contribution of genetic risk variants to disease susceptibility and fibrosis progression remains poorly characterised. We investigated the association of 12 candidate SNPs with MASLD susceptibility and fibrosis severity in North Indian patients, benchmarking allele frequencies against IndiGenomes and global populations. MethodsSixty-nine MASLD patients (75.4% male; median BMI 29.8 kg/m{superscript 2}) from a tertiary care liver clinic in New Delhi were genotyped for 12 SNPs using Illumina custom BeadChip array and Sanger sequencing. Patients were stratified by liver stiffness measurement (LSM): significant fibrosis ([&ge;]8 kPa, n=38) versus no significant fibrosis (<8 kPa, n=31). Allele frequencies were compared with IndiGenomes ([~]1,020 Indian individuals) and 1000 Genomes populations. ResultsPNPLA3 rs738409 G allele was the strongest within-cohort predictor of significant fibrosis (allelic OR 2.89, 95% CI 1.35-6.19, P=0.006; dominant model OR 3.94, P=0.008), with carriers demonstrating higher LSM (median 15.6 vs. 7.5 kPa, P=0.005). SAMM50 rs3761472 (OR 2.12, P=0.065) and FTO rs9939609 (OR 2.08, P=0.089) showed non-significant trends. In the population-level comparison, APOC3 rs2854116 T allele was the only variant significantly enriched after Bonferroni correction (64.0% vs. 47.9%; OR 1.93, 95% CI 1.35-2.77, P<0.001), followed by PNPLA3 (33.3% vs. 24.1%, OR 1.57, P=0.019) and SAMM50 (31.2% vs. 22.6%, OR 1.55, P=0.028). Notably, APOC3 showed no association with fibrosis (OR 0.96, P=1.000), suggesting a role in susceptibility rather than progression. All SNPs were in Hardy-Weinberg equilibrium. ConclusionsThis study reveals a dissociation between genetic determinants of MASLD susceptibility and fibrosis progression in North Indian patients. APOC3 rs2854116 predisposes to MASLD at the population level, while PNPLA3 rs738409 drives fibrosis severity within established disease, underscoring the need for ancestry-specific genetic risk stratification. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/26347059v1_ufig1.gif" ALT="Figure 1"> View larger version (69K): org.highwire.dtl.DTLVardef@187f189org.highwire.dtl.DTLVardef@25d3borg.highwire.dtl.DTLVardef@13704e9org.highwire.dtl.DTLVardef@1238cce_HPS_FORMAT_FIGEXP M_FIG C_FIG

BackgroundDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) enables non-invasive characterization of carotid atherosclerotic plaque. PurposeTo evaluate the performance and reproducibility of a simplified DCE-MRI quantification method for carotid plaque assessment. MethodsT1-weighted black-blood DCE-MRI of the carotid arteries at 3T was performed at baseline and after six months in patients with mild-to-moderate atherosclerotic lesions in a pilot placebo-controlled randomized trial evaluating the effects of low-dose (0.5mg daily) colchicine therapy on carotid plaque volume. DCE-MRI signal intensity was measured in manually drawn regions of interest in the plaque core, remote non-atherosclerotic vessel wall, and skeletal muscle. Peak signal intensities were normalized to skeletal muscle signal in the same slice. ResultsIn patients (n=28, median [interquartile range] age 72 [64-74] years, 36% female, n=13/15 colchicine/placebo), normalized peak signal intensity was higher in the plaque core than in the remote vessel wall at both baseline (3.5 [2.3-4.1] vs 2.1 [1.7-2.5], p<0.001) and follow-up (3.2 [2.5-4.4] vs 2.0 [1.7-2.5], p<0.001). Measurements did not differ between baseline and follow-up for all patients (0.7{+/-}0.7 for plaque core, 0.6{+/-}0.4 for remote vessel wall, p>0.80 for both) nor between colchicine intervention and placebo control (p>0.35 for either region). ConclusionsNormalised peak signal intensity on DCE-MRI was consistently higher in the carotid plaque core than in the remote vessel wall, showed excellent reproducibility in both regions over six months, and was not altered by colchicine treatment. This simplified, muscle-normalised approach may facilitate future studies exploring DCE-MRI measures potentially related to plaque vulnerability.

BackgroundAlthough ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) are very similar regarding pathophysiology and clinical treatments, especially NSTEMI comprises a much more heterogenic group of patients and underlying diseases. We therefore aimed to assess the treatments and outcomes of both entities in a large contemporary cohort. MethodsPatients with STEMI and NSTEMI between 01/2010 to 12/2018 were identified from the largest German Health Insurance (AOK, {approx}26 million members). Patient demographics, their hospital course, adherence to guideline-directed drug therapy and overall survival were assessed. ResultsIn total 544,529 patients (mean age 74, IQR 62-82), one third of whom had a STEMI. Chronic kidney disease, peripheral arterial disease, and heart failure were more common in patients with NSTEMI. Patients with STEMI were more likely to get coronary angiograms and percutaneous coronary interventions. Although STEMI more frequently led to cardiogenic shock, the rate of serious cardiac events was lower. Mortality was higher for STEMI only within the first 30 days, whereas long-term survival rates were better. The combination of statins, angiotensin converting enzyme inhibitors /angiotensin receptor blockers, beta blockers, and oral anticoagulants or antiplatelet agents was associated with higher overall survival in patients with STEMI (hazard ratio [HR] 0.20; 95% confidence interval [95%CI] 0.18 - 0.24; p<0.001) or NSTEMI (HR 0.30; 95%CI 0.28 - 0.33; p<0.001). Nevertheless, the prescription rates decreased over time, particular in patients with NSTEMI. ConclusionClear differences between STEMI and NSTEMI were observed regarding short-and long-term survival. Guideline-recommended therapy improved long-term survival, but decreased during the follow-up period.

BackgroundSepsis is a major public health challenge, and reliable biomarkers are essential for distinguishing sepsis from other conditions. Neutrophil Gelatinase-Associated Lipocalin (Neutrophil gelatinase-associated lipocalin (NGAL)) has shown promise as a diagnostic marker due to its role in the immune response. This study evaluates plasma NGAL as a diagnostic tool at the time of ICU admission. MethodsWe analysed plasma NGAL and C-reactive protein (CRP) levels in 4732 adult patients admitted to four ICUs between 2015 and 2018. All patients were retrospectively screened for Sepsis-3 criteria at ICU admission. The discriminative performance of NGAL and CRP for sepsis was assessed using receiver operating characteristic (ROC) analysis, with NGAL levels adjusted for Chronic kidney disease (CKD) and age. Patients were stratified by renal function. ResultsPlasma NGAL levels were significantly higher in septic patients (p<0.001). For the whole cohort, NGAL alone yielded an Area under the curve (AUC) of 0.67 (Confidence interval (CI) 0.66-0.69), CRP yielded an AUC of 0.72 (CI 0.71-0.73, p<0.001), and combining NGAL with CRP nominally improved discriminative performance (AUC 0.74 vs 0.72, p<0.001). Stratified analyses indicated that NGAL, together with CRP, significantly outperformed CRP alone in patients with no kidney injury and those with Acute Kidney Injury (AKI) only. In contrast, differences were not significant in patients with CKD only or CKD and AKI. ConclusionIn this large cohort, NGAL showed modest discrimination for sepsis, with a nominal improvement when combined with CRP. These findings do not indicate that NGAL meaningfully improves sepsis diagnosis in the ICU.

BackgroundCirculating lipoprotein(a) [Lp(a)] levels are highly heritable and linked to atherosclerotic cardiovascular disease, yet clinical measurement rates remain low (<1%) in the United States. The high heritability of Lp(a) across populations makes genetic prediction an attractive approach for closing this testing gap, but existing polygenic scores transfer poorly across populations. Haplotype-based prediction models, which use standard genome-wide genotype data to capture common-, rare-, and structural-variation at the LPA locus, could bridge this gap, enabling opportunistic identification of individuals with elevated Lp(a) levels across diverse populations within existing large, genotyped cohorts. ObjectivesThis study sought to develop and validate a haplotype-based prediction model using genome-wide genotype data to identify individuals with elevated Lp(a) levels across diverse populations. MethodsWe developed an LPA-haplotype model using data from the All of Us Research Program and validated it in the Penn Medicine BioBank (PMBB), Mass General Brigham Biobank (MGBB), and Mount Sinai BioMe cohorts. Primary outcomes included model performance for predicting continuous Lp(a) concentrations (r{superscript 2}) and identifying elevated Lp(a) levels (>125 nmol/L) through positive predictive value (PPV) and number needed to test (NNT). ResultsAmong PMBB (n = 1856), MGBB (n = 1401), and BioMe (n = 1686) participants with available genotype and Lp(a) measurements, average age was 60 years, and 51% were female. Overall r{superscript 2} of the haplotype model was 0.46 (95% Credible Interval [CrI] 0.32 to 0.6), with similar performance across genetically inferred ancestries and cohorts. For identifying elevated Lp(a) levels >125 nmol/L the overall PPV was 0.81 (95% CrI 0.6 to 0.89), corresponding to a NNT of 1.2 (95% CrI 1.1 to 1.7) individuals predicted to have elevated levels needing to undergo clinical testing to identify one true elevation. In the full PMBB cohort (n = 49310), the haplotype model identified elevated Lp(a) at a rate of 128 per 1000 (95% CrI 125 to 130), corresponding to an estimated 14.4-fold improvement (95% CrI 13.1 to 15.9; P(improvement) = 1) in identification rate compared with the existing rate of clinical assessment. ConclusionsA haplotype-based genetic model effectively identified individuals with elevated Lp(a) levels across diverse populations, with potential utility for opportunistic screening among cohorts where genotype data is available, but Lp(a) testing rates are low.

PurposePortal hypertension, a major complication of chronic liver disease, leads to significant morbidity and mortality. While portal vein diameter measured on imaging has long been proposed as a non-invasive marker of portal hypertension, normative CT-based reference values and population-level associations remain incompletely characterized. Here, we aim to define contemporary reference values for portal vein diameter on clinically obtained CT and evaluate its associations with demographic, clinical, and imaging factors, as well as its diagnostic performance for portal hypertension. MethodsWe conducted a retrospective analysis of 20,225 clinically obtained CT scans at a single academic medical center. The main portal vein was automatically segmented using Total Segmentator, and maximum diameter extracted using the Vascular Modeling Toolkit. Associations with demographic and imaging factors were evaluated using linear mixed-effects models; prevalent liver disease and portal hypertension using logistic regression; risk of incident ascites and esophageal varices among participants with liver disease using Cox regression; and invasive hepatic venous pressures using correlation analysis and linear regression. ResultsThe mean portal vein diameter was 12.4 mm (95% CI, 12.37-12.45). Larger diameter was independently associated with male sex (+1.4 mm), higher BMI (+0.11 mm/kg/m2), greater height (+0.04 mm/cm), and older age (+0.05 mm/10 years) (all p <0.001), and was substantially larger on contrast-enhanced abdomen/pelvis CT (+2.4 mm, p <0.001). Each 1-mm increase in portal vein diameter was associated with higher odds of prevalent liver disease (OR 1.06; 95% CI, 1.04-1.08) and portal hypertension (OR 1.18; 95% CI, 1.12-1.28). Among individuals with liver disease, greater diameter predicted higher risk of incident esophageal varices (baseline diameter HR 1.50; 95% CI, 1.14-2.08) and ascites (HR per mm increase in diameter 1.06; 95% CI, 1.003-1.12). However, portal vein diameter demonstrated weak to no association with invasively measured hepatic venous pressures. ConclusionIn this large, EHR-linked imaging cohort, the mean portal vein diameter on CT was 12.4 mm and varied with demographic and imaging factors. Larger diameter was associated with liver disease, portal hypertension, and subsequent development of varices and ascites, supporting use of portal vein diameter as a pragmatic screening or enrichment tool within multimodal clinical frameworks. Key ResultsO_LIMean portal vein diameter on routine clinical CT was 12.4 mm (95% CI, 12.37-12.45) and varied with sex, height, BMI, exam type, contrast use, and clinical setting. C_LIO_LIEach 1-mm increase in portal vein diameter was associated with higher odds of prevalent liver disease (OR 1.06) and portal hypertension (OR 1.18). C_LIO_LIAmong individuals with liver disease, larger portal vein diameter predicted higher risk of incident esophageal varices and ascites, independent of demographic and imaging factors. C_LI

ImportanceRecent reports have highlighted an intense influenza activity related to the circulation of the influenza A(H3N2) subclade k variant. There is no data available on the impact of the emergence of H3N2 subclade k on the severity of the 2025-2026 epidemic or on the clinical phenotype of patients requiring admission to the intensive care unit (ICU). ObjectiveTo compare the clinical presentation, hospital mortality and virological characteristics of patients with laboratory-confirmed influenza infection included in French intensive care units during the 2025-2026 epidemic season with those of patients admitted during the 2024-2025 season. We also aimed at measuring the impact of the A(H3N2) subtype on hospital mortality during the 2025-2026 season. DesignProspective, multicenter, observational SEVARVIR cohort study including patients admitted during the 2024-2025 and 2025-2025 influenza seasons. SettingForty-two French ICUs ParticipantsAdult patients with laboratory-confirmed influenza infection Interventionsnone Main Outcomes and MeasuresThe primary outcome measure was in-hospital mortality. ResultsPatients admitted in intensive care units for influenza in 2024-2025 (n=360) and 2025-2026 (n=325) were included in the French nationwide prospective multicentre SEVARVIR study. There was no significant difference in day-28 mortality between the seasons (12.7%, n=45/355 vs 16.5% n=28/170; p=0.28). In the 2025-26 season, 49% had the A(H1N1) subtype and 51% the A(H3N2) subtype (k subclade: 77%). The univariable Cox analysis revealed that patients infected with A(H3N2) viruses were at greater risk of death over time. Multivariable Cox analysis revealed that during the 2025-2026 season, age (adjusted hazard ratio, aHR=1.05 [1.00;1.11]; p=0.046) and the clinical frailty scale (aHR=1.82 [1.26;2.72]; p=0.001) were associated with an increased risk of death. The A(H3N2) subtype was not associated with an increased risk of death (aHR=1.13 [0.32;4.51]; p=0.85). Phylogenetic analyses from our ICU cohort together with 300 contextual sequences from community-acquired influenza cases collected during the same period showed no clustering according to severity. Conclusions and RelevanceThis French national prospective observational study, found that the emergence of the influenza A(H3N2) subclade K was associated with an increased risk of death in univariable but not multivariable analysis, adjusting for host-related factors. Trial RegistrationNCT051625 Key PointsQuestion: What impact did the 2025-26 influenza epidemic and the A(H3N2) variant have on the mortality of patients admitted to intensive care units? Findings: In this prospective, nationwide cohort study of 685 patients admitted to intensive care units with severe influenza during the 2024-25 or 2025-26 seasons, no difference in hospital mortality was observed between the two seasons. Patients infected with the A(H3N2) virus, 77% of which corresponded to clade k, were at higher risk of death in univariable but not in multivariable analysis after adjusting for age and clinical frailty scale. Meaning: Patients in intensive care units with severe A(H3N2) infection during the 2025/2026 season were not at higher risk of death after adjusting for confounding variables.

AimsThis study aimed to examine the prevalence of malnutrition and its associations with functional capacity and quality of life (QoL) in AL and ATTR cardiac amyloidosis patients. Methods and ResultsThis cross-sectional pilot study included 29 patients with confirmed CA (14 AL, 15 ATTR). Data were collected between January 2020 and September 2021. Nutritional status was assessed using body mass index (BMI), anthropometric measures, and the Subjective Global Assessment (SGA). Functional capacity was evaluated via handgrip strength and the 6-minute walk test, while QoL was assessed using the SF-36 and Kansas City Cardiomyopathy Questionnaire. Malnutrition, as determined by SGA, was present in 62% of patients, with no significant difference between AL and ATTR subtypes. In contrast, BMI according to WHO criteria failed to identify any cases of malnutrition, highlighting its limited utility in this population. These results suggest that conventional indicators may underestimate nutritional impairment in CA. Although overall QoL and functional capacity did not differ significantly between nutritional groups, malnourished AL patients showed notably lower QoL scores compared with well-nourished peers. ConclusionMalnutrition is highly prevalent in cardiac amyloidosis and seems to particularly affect the AL subtype. These findings underscore the importance of routine nutritional screening and targeted interventions, as early identification and management of malnutrition may improve patients quality of life and long-term outcomes.

BackgroundThere is uncertainty among physicians regarding the optimal clinical application of the novel high-sensitivity cardiac troponin I (hs-cTnI)-VITROS assay within the widely implemented upper reference limit (URL)-based ESC 0/3h-algorithm. MethodsThis prospective, international, multicenter study aimed to validate and compare different modifications of the URL-based ESC 0/3h-algorithm among adult patients presenting with suspected acute myocardial infarction (AMI) to the emergency department. Final diagnoses of AMI were centrally adjudicated by two independent cardiologists, blinded to hs-cTnI-VITROS concentrations. Discrimination was compared to the best validated hs-cTnT/I-assays. Clinical follow-up for cardiovascular death and AMI was conducted until five years. ResultsAmong 1225 eligible patients (median age 63 years (IQR 52-75), 31.9% women), 18.9% were adjudicated as NSTEMI. Diagnostic discrimination of hs-cTnI-VITROS at 0h was very high (AUC 0.949, 95% CI 0.941-0.958), and comparable to hs-cTnI-Architect and hs-cTnT-Elecsys. Using the ESC 0/3h algorithm, 30.9% of patients were classified as rule-out (sensitivity 99.1%, NPV 99.5%) and 19.0% as rule-in (specificity 96.0%, PPV 82.8%). Substituting the HEART score for the GRACE score increased rule-out efficacy to 43.9%, while maintaining very high safety (sensitivity 99.6%; NPV 99.8%). Findings were consistent across predefined subgroups, in sensitivity analyses restricted to type 1 NSTEMI, using the 2h study blood sample (n=2249), and for the composite of cardiovascular death or AMI during five-year follow-up. ConclusionsThe ESC 0/3h-algorithm demonstrated excellent performance for rule-out of NSTEMI with greater efficacy when combined with the HEART-instead of the GRACE score. Registrationhttps://clinicaltrials.gov/study/NCT00470587 Clinical PerspectiveO_ST_ABSWhat Is New?C_ST_ABSO_LIIn a prospective, international multicenter cohort, the URL-based ESC 0/3h algorithm using the FDA-cleared hs-cTnI-VITROS assay achieved very high rule-out safety (sensitivity 99.1%, NPV 99.5%) but limited efficacy (30.9% rule-out) when combined with GRACE score <140 and symptom resolution. C_LIO_LIReplacing GRACE with a HEART score (<5) increased rule-out efficacy to 43.9% while maintaining excellent safety (sensitivity 99.6%, NPV 99.8%), with consistent findings across subgroups, sensitivity analyses, and long-term outcomes. C_LI What Are the Clinical Implications?O_LIClinicians and health systems using hs-cTnI-VITROS can apply the ESC 0/3h algorithm with assay-conform decision values; adding clinical risk stratification is necessary to meet contemporary rule-out safety targets. C_LI

ObjectiveDespite substantial variability in the severity of post-anoxic encephalopathy, all comatose patients after cardiac arrest are usually treated according to the same standardized intensive care protocol, including sedation, mechanical ventilation, and targeted temperature management (TTM). We hypothesize that patients with a favourable EEG pattern (continuous EEG within 12 hours after cardiac arrest) may not benefit from prolonged sedation and TTM. We studied the feasibility and safety of early cessation of sedation and TTM in this subgroup. MethodsWe conducted a non-randomized, controlled intervention study including 40 adult patients admitted to the ICU with postanoxic encephalopathy after cardiac arrest and an early (< 12 hours) favourable EEG pattern. The control group received standard care with sedation and TTM for at least 24-48 hours, whereas the intervention group underwent early cessation of sedation and TTM as soon as possible after establishing a favourable EEG, followed by weaning from mechanical ventilation. The primary outcome was duration of mechanical ventilation. Secondary outcomes included ICU length of stay, total sedation time, number of ICU complications, and neurological outcomes at 3 and 6 months. ResultsDuration of mechanical ventilation was significantly shorter in the intervention than in the control group (median 12 vs 28 h, p < 0.001). Median ICU length of stay and median total sedation time were also reduced by more than 50% in the intervention group, from respectively 2.5 to 1.2 days (p = 0.001) and 27 to 12 h (p < 0.001). There was no increase in ICU complications in the intervention group. No statistically significant differences in neurological outcomes at 3 or 6 months were observed. ConclusionEarly withdrawal of sedation is feasible and safe in patients with an early favourable EEG following cardiac arrest. The study was underpowered to detect possible differences in long-term neurological recovery. SignificanceShortening sedation and mechanical ventilation is likely to result in direct reductions in healthcare costs and contribute to more appropriate care. Larger studies are needed to evaluate the impact on long-term neurological outcomes.

ObjectiveTo analyze the experience of the last six years with ECMO in Uncontrolled Donation after Circulatory Death (uDCD), assessing the clinical and logistical factors that determine donation effectiveness and the viability of retrieved organs, with the nurse perfusionist as the central figure in organ perfusion. MethodsRetrospective observational study of uDCD procedures performed at Hospital Clinic de Barcelona between June 2019 and October 2025. ResultsOf 184 out-of-hospital ECMO-CPR activations, 108 (58.7%) underwent perfusion; 72 donor cases (66.7%) were generated, and 109 kidneys (75.7%) and 3 livers (4.15%) were retrieved. The annual number of uDCD donors was heterogeneous. Compared with non-effective donors, effective donors were significantly younger (48.1 {+/-} 12.4 vs 53.0 {+/-} 10.7 years, p=0.03) and had fewer comorbidities such as hypertension (13.8% vs 33.0%, p=0.018) and diabetes (4.1% vs 16.6%, p=0.027). Although effective donors had a shorter cannulation time (25.6 {+/-} 13.9 vs 29.1 {+/-} 11.9 min, p=0.09), the difference was not statistically significant; however, cardiocompressor time did show a significant difference (58.9 {+/-} 17.7 vs 65.8 {+/-} 18.2 min, p=0.03). ConclusionsuDCD was a useful source of transplantable organs, mainly kidneys (two out of every three perfused patients became donors), in the current context of scarcity of brain-dead donors. Shorter warm ischemia times (cardiocompressor and cannulation times) were significantly associated with more effective organ donation. The multidisciplinary transplant team may benefit from perfusion professionals with expertise in extracorporeal oxygenation therapy.

BackgroundPulse oximeters are typically validated on cohorts of 200-500 subjects under controlled conditions. Whether these cohorts capture the demographic heterogeneity of national clinical practice -- and whether measurement error is associated with patient outcomes -- has not been established at scale. MethodsWe analyzed paired SpO2/SaO2 readings from three independent sources spanning 209 U.S. hospitals: MIMIC-IV (1 hospital; 12,934 ICU stays), eICU-CRD (208 hospitals; 55,178 stays), and the Open Oximetry Repository (PhysioNet; 52.4 million readings with continuous melanin and perfusion indices). Bias was defined as SpO2 - SaO2. Hidden hypoxemia (SpO2 [&ge;] 94% with SaO2 < 88%) was assessed per ICU stay. Mortality was compared between hidden-hypoxemia-positive and -negative stays with multivariable logistic regression adjusting for age, sex, race, and four laboratory severity markers (cluster-robust SEs by hospital). Sensitivity analyses included landmark restriction (first 48 hours), lactate stratification, alternate thresholds, and patient-level aggregation. PPG signal quality was assessed in 125 ICU patients with demographic-linked waveform data. ResultsBias was minimal at normal perfusion but amplified under low perfusion in high-melanin patients, consistent with known optics: at very low perfusion x high melanin x severe hypoxia, mean bias reached +12.8% (n = 458,571), with 47% of readings constituting hidden severe hypoxemia. National bias in African American patients was +2.76% (n = 529,541; 208 hospitals), 62% higher than academic estimates. Across 55,178 eICU stays, hidden hypoxemia was associated with approximately doubled mortality after adjustment for age, sex, race, and illness severity (adjusted OR 1.86, 95% CI 1.69-2.04, p < 0.001), consistent across all racial groups. Hidden hypoxemia was not a pre-terminal phenomenon: 63% of events occurred >48 hours before death (median first event: 15.3 hours; mean time to death: 151 hours), and the association persisted in landmark analysis (first 48 hours only), in patients with normal lactate (adjusted OR 1.87, 95% CI 1.61-2.16), and when both restrictions were applied simultaneously (16.5% vs. 11.1%). Waveform analysis (n = 125) showed no fixed racial difference in baseline PPG AC/DC ratio (Black: 0.299, White: 0.273), suggesting the signal deficit is conditional on perfusion state. Full extraction (n = 1,545) is in progress. ConclusionsIn this multicenter retrospective analysis, national pulse oximetry variance exceeded published benchmarks and was associated with approximately doubled ICU mortality, replicated across 209 U.S. hospitals. Hidden hypoxemia was not a pre-terminal artifact: events occurred throughout the ICU stay at a constant rate, and mortality associations persisted in landmark and lactate-stratified analyses. These findings suggest that current regulatory validation standards may underestimate the real-world prevalence of demographic bias in pulse oximetry, and that perfusion-dependent mechanisms may offer a target for algorithmic correction.

3D-DXA reconstructs DXA hip scans to 3-dimensional images allowing measurement of trabecular and cortical bone parameters. Given the higher image quality of GE Healthcare iDXA than GE Healthcare Prodigy, it could be hypothesized that the reconstruction might differ, thereby affecting 3D-DXA results. The aim of the study was to assess agreement and precision of 3D-DXA cortical and trabecular femur parameters between Prodigy and iDXA densitometers in adult subjects. The study cohort was composed of 391 men and women recruited from 3 clinical centers (USA and Brazil). All subjects were scanned on either Prodigy or iDXA scanners. Short-term precision was assessed on two Prodigy and two iDXA densitometers. 3D-DXA analyses were performed using 3D-Shaper software version 2.14. Agreement between densitometers was assessed by regression and Bland-Altman analyses. Short-term precision was determined following International Society for Clinical Densitometry recommendations. Strong agreements for 3D-DXA parameters were obtained between devices regardless of the center or the DXA device model (all R2 > 0.96). Bland-Altman analyses demonstrated statistically (p < 0.05), but not clinically, significant difference between both aBMD and 3D-DXA measurements obtained using Prodigy and iDXA scanners. Short-term precision of areal BMD and 3D-DXA parameters was similar between densitometers. This study demonstrated excellent 3D-DXA measurement agreement and similar precision between iDXA and Prodigy densitometers. These data provide evidence that no adjustments are required when using 3D-Shaper software on iDXA or Prodigy instruments. Mini AbstractWe assessed agreement and precision of 3D-DXA parameters between GE Healthcare Prodigy and iDXA densitometers in adults. Strong agreement was observed between devices, and short-term precision was comparable. Findings indicate that no adjustment is needed when using 3D-DXA with GE Healthcare densitometers.

BackgroundAnthracyclines are central to childhood cancer therapy but predispose patients to cardiotoxicity leading to long-term cardiovascular risk. Endothelial injury and impaired repair contribute to this, yet pediatric data remain limited. ObjectiveTo longitudinally assess endothelial injury and repair in childhood cancer patients treated with anthracyclines by quantifying circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs). MethodsIn a single-centre retrospective cohort, children (<18 years) diagnosed with leukemia (n=35) or lymphoma (n=13) were studied at four timepoints: pre-treatment ("Pre"), [~]1-month- ("End"), 3 months- (3M), and 1 year- (1Y) post-treatment. Peripheral blood mononuclear cells were analyzed by flow cytometry to quantify CECs and EPCs, and EPC fate was assessed by p16 (senescence) and Annexin V (apoptosis). Cardiac injury biomarkers and left ventricular function were assessed at each timepoint. ResultsLongitudinal trends of CEC and EPC counts were similar between leukemia and lymphoma participants. CECs were highest at pre-treatment and declined significantly thereafter, though they remained marginally elevated during remission compared with healthy controls, indicating that endothelial damage had largely subsided following treatment. EPCs were also highest at pre-treatment and decreased to levels below healthy controls during remission, suggesting impaired baseline endothelial maintenance and repair. Furthermore, EPCs were predominantly senescent up to 1-year post-treatment. ConclusionsEndothelial injury resolves by treatment completion, but repair remains impaired during remission with EPC pools dominated by senescent cells. This suggests defective endothelial regeneration, rather than persistent injury, drives long-term cardiovascular complications and underscores the need to restore EPC viability and function in childhood cancer survivors.

ObjectivesTo develop and validate pediatric adaptations of the Venous Excess Ultrasound Score (P-VExUS) for noninvasive estimation of central venous pressure (CVP) in critically ill children. DesignProspective observational study. SettingPICU of a tertiary-care teaching hospital. PatientsFifty-six mechanically ventilated children (median age 7.4 months, median weight 6.0 kg) with central venous catheters. InterventionsNone. Measurements and Main ResultsVenous Doppler ultrasonography of the inferior vena cava, hepatic, portal, and intrarenal veins was performed at the bedside. Two P-VExUS models were tested: (1) a categorical grading system (0-III) and (2) a semiquantitative point-based score (0-7). Both models showed significant associations with CVP. For predicting elevated CVP (>12 mmHg), model 1 achieved an AUROC of 0.74 (95% CI 0.61-0.85) with 45% sensitivity and 98% specificity, while model 2 demonstrated superior accuracy with an AUROC of 0.94 (95% CI 0.84-0.98), sensitivity 82%, and specificity 91% (p < 0.001). For detecting low CVP (<7 mmHg), model 2 also outperformed model 1 (AUROC 0.80 vs. 0.69, p = 0.02). Among individual venous Doppler components, intrarenal veins had the highest discriminative ability (AUROC 0.92), followed by hepatic (0.89) and portal (0.80) veins. ConclusionsTwo pediatric-specific P-VExUS models were feasible and accurate for estimating CVP in critically ill children. The point-based model (model 2) demonstrated superior diagnostic performance, supporting its potential as a noninvasive tool to assess venous congestion at the bedside. Research in ContextO_LIVenous congestion, reflected by elevated central venous pressure (CVP), is associated with adverse outcomes in critically ill children, including mortality and renal dysfunction. C_LIO_LIThe Venous Excess Ultrasound Score (VExUS) is validated in adults, but pediatric-specific adaptations and cutoff values remain poorly defined. C_LIO_LIThere is a need for noninvasive, bedside tools to estimate CVP in children and guide fluid management in the PICU. C_LI What This Study MeansO_LIThis study validates pediatric-specific adaptations of the Venous Excess Ultrasound Score (P-VExUS) for estimating CVP in critically ill children. C_LIO_LIThe semiquantitative point-based model provided more consistent and accurate discrimination of venous congestion compared with categorical grading. C_LIO_LIThese findings highlight the feasibility and potential clinical utility of venous Doppler ultrasonography as a noninvasive bedside tool in the PICU. C_LI

BackgroundMulti-system impacts of long COVID remain unknown. We compared multi-system deficits between people with long COVID and controls. MethodsA case-control study recruited from the Avon Longitudinal Study of Parents and Children and TwinsUK population cohorts. Cases (141) had long COVID (evidence of COVID-19 infection and persistent symptoms [&ge;]4 weeks post infection); controls (280) included people making a full recovery in <4 weeks, people self-reporting long COVID like symptoms but without wild-type SARS-CoV-2 virus antibodies, and people without symptoms or history of COVID-19 infection. Participants underwent multi-system MRI, (cardiac, brain, lung, kidney), measurement of blood pressure and autonomic function, tests of exercise performance, spirometry, renal function, strength and physical capability. System-specific deficits were summed to a total potential score of 27. FindingsParticipants attended clinic between 2021-23. Overall deficit score in cases was 0.22 (95% CI -0.44,0.88) units greater than controls, adjusted for age, sex, ethnicity, cohort membership and relatedness. This estimate was little changed (0.32 (-0.34, 0.98)) when additionally adjusted for educational status, index of multiple deprivation, physical activity, smoking and co-morbidity. Restricting cases to those reporting at least fatigue (46) increased the excess deficit score to 0.81 (-0.19,1.81) units in the minimally adjusted model. A difference was only observed in the vascular domain, largely attributable to elevated blood pressure, showing a 1.76 (1.04,2.97) multivariable adjusted odds ratio excess in cases, and 3.04 (1.36,6.80) when restricted to cases with fatigue. InterpretationPeople with community-based long COVID should be reassured that there is not marked residual deficit across multiple systems. However, blood pressure measurement and control should be included in clinical follow-up. FundingJointly funded by the National Institute for Health and Care Research and UK Research and Innovation (CONVALESCENCE, COV-LT-0009, MC_PC_20051).

Background Short-chain fatty acids (SCFAs) are widely used as functional readouts of gut microbial activity in vivo. The growing adoption of decentralised study designs and self-collection protocols has amplified the need for reliable room-temperature storage and shipment strategies. However, SCFAs volatility and the persistence of post-collection microbial metabolism raise concerns regarding pre-analytical stability and the interpretability of measured concentrations. Methods We assessed the temporal stability of fatty acids (FAs) across intestinal and systemic matrices under room-temperature storage. Untreated stool was compared with two nucleic acid stabilisation devices (eNAT and OMNIgene-GUT), while whole blood, plasma and dried blood spots (DBS) were evaluated as minimally invasive systemic sampling strategies. Profiles were quantified using complementary GC-MS and LC-MS/MS workflows. Results Untreated stool showed fermentation-driven increases in major SCFAs, whereas immediate freezing preserved baseline profiles. eNAT maintained faecal FA stability for up to 21 days, while OMNIgene-GUT exhibited baseline and time-dependent alterations. In systemic matrices, plasma and whole blood showed upward drift, whereas DBS declined initially before stabilising after approximately 14 days. Conclusions FA measurements are highly matrix- and device-dependent. Our findings provide practical guidance for the selection of sampling strategies in microbiome-associated FA studies and emphasise the need for controlled pre-analytical conditions in decentralised microbiome studies.

Background and ObjectivesWhite matter hyperintensities (WMH) of presumed vascular origin are a neuroimaging hallmark of cerebral small vessel disease (CSVD). Their spatial heterogeneity may reflect different clinical phenotypes. Most prior studies relied on principal component analysis to characterise such heterogeneity, which has limited ability to stratify individuals into discrete and interpretable WMH subtypes. We therefore propose a data-driven framework to identify WMH spatial subtypes, characterise their demographic and clinical profiles, and investigate their predictive value for future WMH progression. MethodsWe analysed MRI scans from 63,338 individuals across 4 major cohorts (internal data): ADNI3, Insight46, SABRE and UK Biobank (UKB), and validated our findings in the OASIS-3 dataset (n=844). WMH were automatically segmented and regionally quantified using a 36-region bullseye framework. Clustering was applied to the relative regional distributions of WMH. A stability-based approach was used to identify robust WMH subtypes. Their associations with 19 risk factors of interest were analysed using multivariable regression. In a subset with follow-up MRI scans (internal: n=5,274, OASIS-3: n=182), we evaluated the predictive value of these subtypes combined with other volumetric or spatial WMH variables for WMH progression. ResultsFive WMH location patterns with different lesion burden and spatial distribution were identified (stability score 0.946) and reproduced in OASIS-3. These patterns showed distinct associations with demographic, vascular, metabolic, inflammatory and genetic risk factors. Higher-burden patterns were independently associated with older age, higher blood pressure, diabetes and smoking, indicating a gradient of vascular risk across spatial subtypes. WMH location patterns were largely preserved over 18-30 months, with most individuals remaining within the same pattern (71.5%). While global baseline WMH volume remained a strong predictor of future WMH progression (balanced accuracy 0.693, 95% CI: 0.664-0.723), models including baseline regional WMH volumes consistently outperformed other candidates (best balanced accuracy 0.737, 95% CI: 0.706-0.764). DiscussionWe presented a robust and scalable framework for spatial WMH phenotyping. We discussed clinical and prognostic implications of the spatial subtypes beyond total lesion burden. Our findings supported the value of WMH spatial characterisation in stratifying risk that may help guide personalised approaches to managing CSVD.

BackgroundQuality measurement in intensive care emphasizes task completion--whether assessments were documented and protocols followed. Electronic health record (EHR) systems capture these signals in real time, yet current metrics cannot distinguish task completion from cognitive clinical engagement. A prior analysis demonstrated that omission of orientation assessment predicted a 4.29-fold increase in hospital mortality among low-acuity ICU patients [1]. Whether combining this marker with routine task-completion data yields a computable phenotype with independent prognostic value has not been studied. ObjectiveTo define, validate, and characterize "discordant care"--a computable EHR phenotype defined as completion of [&ge;]6 of 8 routine nursing assessments without orientation assessment documentation--as a predictor of hospital mortality, distinguishing patient-level confounding from care process signal. MethodsRetrospective cohort study using MIMIC-IV v3.1 (2008-2022), including 46,004 adult ICU stays with SOFA scores 0-2 and length of stay [&ge;]24 hours in non-neurological ICUs. Primary exposure: discordant care, computed from structured nursing flowsheet data within 24 hours of admission. Primary outcome: hospital mortality. Progressive covariate adjustment included mechanical ventilation, sedation, and diagnosis. ResultsDiscordant care was present in 8891 patients (19.3%), with 69.7% mechanically ventilated versus 25.3% of concordant patients. Two overlapping signals were identified: a patient-level signal driven by ventilation/sedation (full adjustment OR 1.19, 95% CI 1.09-1.30) and a care process signal in non-ventilated patients (OR 2.14, 1.87-2.44; N=30,314). Among non-ventilated SOFA 0 patients, OR was 2.60 (2.13-3.18; N=16,295). The signal was present across all 7 major diagnosis categories. Quantitative bias analysis indicated unmeasured delirium could attenuate but likely not fully explain the non-ventilated signal. ConclusionsDiscordant care identifies two phenomena: a patient-level signal from ventilation/sedation and a care process signal where assessable patients receive routine care without cognitive engagement (OR 2.14-2.60). This care process signal is invisible to existing quality metrics and detectable in real time. Prospective validation with systematic delirium screening is needed.

BackgroundInhaled combusted cannabis and co-use of combusted cannabis and nicotine electronic cigarettes (nECIGs) are on the rise, yet their long-term cardiovascular risk is unclear due to the high prevalence of confounders in observational human studies. Using primary plasma and monocytes and a novel ex vivo mechanistic model of two early steps in atherogenesis, this study examined whether chronic combusted cannabis use is associated with atherogenic changes, as estimated by 1) monocyte transendothelial migration (MTEM), and 2) monocyte-derived foam cell formation (MDFCF), and whether nECIG co-use further amplifies this risk. MethodsA cross-sectional parallel group comparison study was conducted in healthy adults (21-30 years) who chronically 1) used combusted cannabis, 2) co-used both combusted cannabis and nECIGs, and 3) were non-using controls. Using our ex vivo atherogenesis assay, primary outcomes of MTEM, MDFCF, and median fluorescence intensity (MFI) of the lipid-staining fluorochrome BODIPY were determined using primary plasma and autologous primary monocytes from participants. Using flow cytometry and the fluorochrome CELLROX, cellular oxidative stress (COS) in monocytes was determined. ResultsOf the 134 participants, 59 used cannabis, 26 co-used cannabis/nECIG, and 49 were non-using controls. The groups had similar age, sex, and race. Median MTEM was 1.13 fold greater in people who used cannabis compared to non-users 27.8% (IQR 26.1:29.2%) vs 24.5%, (IQR 22.9:27.4%), p<0.0001, and tended to be greater in people who co-used cannabis/nECIG by 1.22-fold 34.1%, (IQR 29.9:38.3%, p=0.17). Median MDFCF and MFI were also increased in people who used cannabis compared to non-users (MDFCF 36.3%, IQR 31.8:35.8%, vs 26.6%, IQR 23.8:25.8%, 1.36-fold and MFI 1163.8, IQR 1042.8:1155.0, vs 940.2 IQR 849.9:1101.4, 1.24-fold) and were further increased in people who co-used cannabis/nECIG (MDFCF 48.7%, IQR 37.3:52.4%, 1.34-fold, MFI 1433.7, IQR 1263.8:1686.4, 1.23-fold; all comparisons p<0.008). Foam cell formation, but not transendothelial migration, was strongly positively correlated with COS. All primary outcomes increased with greater frequency of cannabis and/or nECIG use. ConclusionsIn healthy young adults, exclusive cannabis use is associated with increased atherogenic properties of monocytes and plasma, and this atherogenic effect is further amplified by co-use of nECIGs.